Population pharmacokinetic modeling as a tool to characterize the decrease in ciprofloxacin free interstitial levels caused by Pseudomonas aeruginosa biofilm lung infection in wistar rats

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Torres, Bruna G S ^a   Helfer, Victória E ^a   Bernardes, Priscila M ^a   MacEdo, Alexandre José ^a   Nielsen, Elisabet I ^b   Friberg, Lena E ^b   Costa, Teresa Dalla ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Biofilm; Ciprofloxacin; Microdialysis; Pneumonia; Population pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BASAL METABOLIC RATE; BIOFILM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ELIMINATION RATE CONSTANT; HEART OUTPUT; INFLAMMATORY INFILTRATE; INTERSTITIAL FLUID; LUNG INFECTION; LUNG VOLUME; MALE; MICRODIALYSIS; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; RAT; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; CIPROFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MICRODIALYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, WISTAR;

EID: 85021925737     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02553-16     Document Type: Article

References (50)

1. Strausbaugh SD, Davis PB. 2007. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 28:279-288. https://doi.org/10.1016/ j.ccm.2007.02.011.
2. Kidd TJ, Ramsay KA, Vidmar S, Carlin JB, Bell SC, Wainwright CE, Grimwood K, ACFBAL Study Investigators. 2015. Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. J Cyst Fibros 14:361-369. https://doi.org/10.1016/j.jcf.2014.12.007.
3. Macia MD, Perez JL, Molin S, Oliver A. 2011. Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. Antimicrob Agents Chemother 55:5230-5237. https://doi.org/10.1128/AAC.00617-11.
4. Ciofu O, Tolker-Nielsen T, Jensen PO, Wang H, Hoiby N. 2015. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev 85:7-23. https:// doi.org/10.1016/j.addr.2014.11.017.
5. Burgess DS, Hall RG. 2007. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Clin Ther 29:1421-1427. https:// doi.org/10.1016/j.clinthera.2007.07.024.
6. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. 2011. Pharmacokinetics/ pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 55: 4469-4474. https://doi.org/10.1128/AAC.00126-11.
7. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. 2012. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 56:2683-2690. https://doi.org/10.1128/AAC.06486-11.
8. Hengzhuang W, Ciofu O, Yang L, Wu H, Song Z, Oliver A, Hoiby N. 2013. High -lactamase levels change the pharmacodynamics of -lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 57:196-204. https://doi.org/10.1128/AAC.01393-12.
9. Hammarlund-Udenaes M. 2006. Microdialysis for characterization of PK/PD relationships, p 589-600. In Handbook of behavioral neuroscience, vol 16. Elsevier Academic Press, San Diego, CA. https://doi.org/10 .1016/S1569-7339(06)16031-2.
10. Zimmermann ES, Laureano JV, Dos Santos CN, Schmidt S, Lagishetty CV, De Castro WV, Dalla Costa T. 2016. Simultaneous semimechanistic population analyses of levofloxacin in plasma, lung, and prostate to describe the influence of efflux transporters on drug distribution following intravenous and intratracheal administration. Antimicrob Agents Chemother 60:946-954. https://doi.org/10.1128/AAC.02317-15.
11. Dhanani J, Roberts JA, Chew M, Lipman J, Boots RJ, Paterson DL, Fraser JF. 2010. Antimicrobial chemotherapy and lung microdialysis: a review. Int J Antimicrob Agents 36:491-500. https://doi.org/10.1016/j.ijantimicag.2010 .08.013.
12. Marchand S, Dahyot C, Lamarche I, Mimoz O, Couet W. 2005. Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats. Antimicrob Agents Chemother 49: 2356-2361. https://doi.org/10.1128/AAC.49.6.2356-2361.2005.
13. Dahyot C, Marchand S, Pessini GL, Pariat C, Debaene B, Couet W, Mimoz O. 2006. Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of Acinetobacter baumannii-infected rats. Antimicrob Agents Chemother 50:2265-2267. https://doi.org/10.1128/ AAC.00190-06.
14. Crandon JL, Kim A, Nicolau DP. 2009. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. Antimicrob Agents Chemother 64:837-839. https://doi.org/10 .1093/jac/dkp301.
15. Kuti JL, Nicolau DP. 2015. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. Int J Antimicrob Agents 45:512-518. https://doi.org/10.1016/j.ijantimicag .2014.12.028.
16. Growcott EJ, Coulthard A, Amison R, Hardaker EL, Saxena V, Malt L, Jones P, Grevot A, Poll C, Osborne C, Banner KH. 2011. Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin. J Cyst Fibros 10:166-174. https://doi.org/ 10.1016/j.jcf.2010.12.007.
17. Yan P, Chen Y, Song Z, Wu H, Kong J, Qin X. 2008. Pathogenic effects of biofilm with chronic Pseudomonas aeruginosa lung infection in rats. J Nanjing Med Univ 22:34 -38. https://doi.org/10.1016/S1007-4376 (08)60007-6.
18. de Lange ECM, de Boer AG, Breimer DD. 2000. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45:125-148. https://doi.org/10.1016/S0169-409X(00)00107-1.
19. Hurtado FK, Weber B, Derendorf H, Hochhaus G, Dalla Costa T. 2014. Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. Antimicrob Agents Chemother 58:678-686. https://doi.org/10.1128/ AAC.01884-13.
20. Boxenbaum H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227. https://doi.org/10.1007/BF01062336.
21. Sweet CS, Emmert SE, Seymour AA, Stabilito II, Oppenheimer L. 1987. Measurement of cardiac output in anesthetized rats by dye dilution using a fiberoptic catheter. J Pharmacol Methods 17:189 -203. https:// doi.org/10.1016/0160-5402(87)90050-7.
22. De Araujo BV, Diniz A, Palma EC, Buffe C, Dalla Costa T. 2011. PK-PD modeling of -lactam antibiotics: in vitro or in vivo models? J Antibiot (Tokyo) 64:439-446. https://doi.org/10.1038/ja.2011.29.
23. Gonzalez D, Schmidt S, Derendorf H. 2013. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev 26:274-288. https://doi.org/10.1128/CMR .00092-12.
24. Gaohua L, Wedagedera J, Small BG, Almond L, Romero K, Hermann D, Hanna D, Jamei M, Gardner I. 2015. Development of a multicompartment permeability-limited lung PBPK model and its application in predicting pulmonary pharmacokinetics of antituberculosis drugs. CPT Pharmacometrics Syst Pharmacol 4:605-613. https://doi.org/10.1002/ psp4.12034.
25. Reisfeld B, Metzler CP, Lyons MA, Mayeno AN, Brooks EJ, Degroote MA. 2012. A physiologically based pharmacokinetic model for capreomycin. Antimicrob Agents Chemother 56:926-934. https://doi.org/10.1128/AAC .05180-11.
26. Zhu L, Zhang Y, Yang J, Wang Y, Zhang J, Zhao Y, Dong W. 2016. Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model. Eur J Drug Metab Pharmacokinet 41:395-402. https://doi.org/10.1007/s13318-015-0271-8.
27. Morgan ET. 2009. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434-438. https://doi.org/10.1038/clpt.2008.302.
28. LeBel M, Bergeron MG, Vallee F, Fiset C, Chasse G, Bigonesse P, Rivard G. 1986. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 30:260-266. https:// doi.org/10.1128/AAC.30.2.260.
29. Vance-Bryan K, Guay D, Rotschafer J. 1990. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 19:434-461. https://doi.org/10.2165/ 00003088-199019060-00003.
30. Gontijo AV, Brillault J, Gregoire N, Lamarche I, Gobin P, Couet W, Marchand S. 2014. Biopharmaceutical characterization of nebulized antimicrobial agents in rats. 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. Antimicrob Agents Chemother 58:3942-3949. https://doi.org/10 .1128/AAC.02818-14.
31. Dan M, Torossian K, Weissberg D, Kitzes R. 1993. The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration. Eur J Clin Pharmacol 44:101-102. https://doi.org/10.1007/BF00315290.
32. Brunner M, Hollenstein U, Delacher S, Jager D, Schmid R, Lackner E, Georgopoulos A, Eichler HG, Muller M. 1999. Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother 43:1307-1309.
33. Cheng PW, Boat TF, Shaikh S, Wang OL, Hu PC, Costa DL. 1995. Differential effects of ozone on lung epithelial lining fluid volume and protein content. Exp Lung Res 21:351-365. https://doi.org/10.3109/01902149509023713.
34. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52:24-36. https://doi.org/10.1128/AAC.00133-06.
35. Davies D. 2003. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2:114-122. https://doi.org/10.1038/nrd1008.
36. Tseng BS, Zhang W, Harrison JJ, Quach TP, Song JL, Penterman J, Singh PK, Chopp DL, Packman AI, Parsek MR. 2013. The extracellular matrix protects Pseudomonas aeruginosa biofilm by limiting the penetration of tobramycin. Environ Microbiol 15:2865-2878. https://doi.org/10.1111/ 1462-2920.12155.
37. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. 2006. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 27:196-200. https://doi.org/10.1016/j .ijantimicag.2005.10.007.
38. Zimmermann E, Torres BG, Dalla Costa T. 2016. Validation of a sensitive HPLC/fluorescence method for assessment of ciprofloxacin levels in plasma and prostate microdialysate samples from rats. Biomed Chromatogr 30:330-336. https://doi.org/10.1002/bmc.3552.
39. Johansen HK, Hoiby N. 1999. Rat model of chronic Pseudomonas aeruginosa lung infection, p 517-529. In Zak O, Sande MA (ed), Handbook of animal models of infection: experimental models in antimicrobial chemotherapy. Elsevier Academic Press, San Diego, CA.
40. Bragonzi A. 2010. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 300:584 -593. https:// doi.org/10.1016/j.ijmm.2010.08.012.
41. van Heeckeren AM, Schluchter MD. 2002. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 36:291-312. https:// doi.org/10.1258/002367702320162405.
42. Tasso L, Bettoni CC, Oliveira LK, Dalla Costa T. 2008. Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats. Int J Pharm 358:96-101. https://doi.org/10.1016/j.ijpharm.2008 .02.023.
43. Li Y, Wang Z, Xiao H, Ning Y, Zhou J, Liu R, Huang Y. 2016. A microdialysis study of pharmacokinetics of orally or intravenously administrated levofloxacin in lung tissues of the Streptococcus pneumoniae pneumonia rat. Int J Clin Exp Med 9:7247-7255.
44. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. 2009. NONMEM users guides (1989-2009). ICON Development Solutions, Ellicott City, MD.
45. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241-257. https://doi.org/10.1016/j.cmpb.2005.04.005.
46. R Core Team. 2012. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
47. Jonsson EN, Karlsson MO. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51-64.
48. Tunblad K, Hammarlund-Udenaes M, Jonsson EN. 2004. An integrated model for the analysis of pharmacokinetic data from microdialysis experiments. Pharm Res 21:1698-1707. https://doi.org/10.1023/B:PHAM .0000041468.00587.c6.
49. Holford NH. 1996. A size standard for pharmacokinetics. Clin Pharmacokinet 30:329-332. https://doi.org/10.2165/00003088-199630050-00001.
50. Dosne AG, Bergstrand M, Harling K, Karlsson MO. 2016. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn 43:583-596. https://doi.org/10.1007/s10928-016-9487-8.